Liquid biopsy is a groundbreaking technique that enables the detection and analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other biomarkers associated with solid cancers, all from a simple blood sample.

In contrast to traditional biopsies, which necessitate invasive procedures to obtain tumor tissue, liquid biopsy is non-invasive and offers critical insights into tumor characteristics.

So many reasons to practice it

Non-invasive

It provides a non-invasive approach to cancer monitoring, in contrast to traditional tissue biopsy methods.

Personalized medicine

It facilitates a personalized care strategy for each patient by identifying their unique antigenic and genetic profiles.

Repeatability

It can be done repeatedly to monitor the progress of the cancer at different timepoints through cancer evolution.

Inexpensive

It is more cost-effective than traditional methods, significantly lowering the costs associated with cancer follow-up care.

Liquid biopsy in clinical routine

Liquid biopsy is intended to improve traditional diagnostic methods, such as tissue biopsies and imaging, by offering a non-invasive alternative. Its accessibility is especially beneficial in medically underserved regions, facilitating effective cancer monitoring even in resource-constrained settings.

Practice it with ScreenCell kits

Liquid biopsy can now be conducted effortlessly using our CYTO and MB kits, which are CE marked for routine clinical applications.

Tell us about your project

Are you interested in establishing a fundamental or clinical research project focused on circulating tumor cells (CTCs) or liquid biopsy?

Share your project details with us, and we will be delighted to assist you in bringing it to fruition.

Liquid biopsy for
enhancing patient care through reliable CTC analysis

Our fields of application

The latest application note

Contact

ScreenCell and liquid biopsy

Liquid biopsy: what is it?